Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Ford

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Investigational New Drugs|January 11, 1990
Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitroS C Barranco, C M Townsend, B Y Ho, et al.
European Journal of Immunology|August 1, 1996
A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathwayS M Scesney, S C Makrides, M L Gosselin, et al.
Oral Microbiology and Immunology|August 17, 2005
Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosisP J Ford, E Gemmell, S M Hamlet, et al.
Gene|December 5, 1996
A tightly regulated high level expression vector that utilizes a thermosensitive lac repressor: production of the human T cell receptor V beta 5.3 in Escherichia coliB Andrews, H Adari, G Hannig, et al.
Oral Microbiology and Immunology|November 19, 2003
Differences in mouse strain influence leukocyte and immunoglobulin phenotype response to Porphyromonas gingivalisE Gemmell, T A Winning, C L Carter, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1996
Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptorS C Makrides, P A Nygren, B Andrews, et al.
Oral Microbiology and Immunology|July 18, 2006
Inflammation, heat shock proteins and periodontal pathogens in atherosclerosis: an immunohistologic studyP J Ford, E Gemmell, A Chan, et al.
Journal of Dental Research|June 4, 2010
High antibody levels to P. gingivalis in cardiovascular diseaseS Bohnstedt, M P Cullinan, P J Ford, et al.
Australian Dental Journal|December 1, 2011
Improved periodontal health and cardiovascular riskS Rose-Hill, P J Ford, S J Leishman, et al.
Protein Science : a Publication of the Protein Society|November 25, 1998
A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinaseT Fox, J T Coll, X Xie, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Investigational New Drugs|January 11, 1990
Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitroS C Barranco, C M Townsend, B Y Ho, et al.
European Journal of Immunology|August 1, 1996
A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathwayS M Scesney, S C Makrides, M L Gosselin, et al.
Oral Microbiology and Immunology|August 17, 2005
Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosisP J Ford, E Gemmell, S M Hamlet, et al.
Gene|December 5, 1996
A tightly regulated high level expression vector that utilizes a thermosensitive lac repressor: production of the human T cell receptor V beta 5.3 in Escherichia coliB Andrews, H Adari, G Hannig, et al.
Oral Microbiology and Immunology|November 19, 2003
Differences in mouse strain influence leukocyte and immunoglobulin phenotype response to Porphyromonas gingivalisE Gemmell, T A Winning, C L Carter, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1996
Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptorS C Makrides, P A Nygren, B Andrews, et al.
Oral Microbiology and Immunology|July 18, 2006
Inflammation, heat shock proteins and periodontal pathogens in atherosclerosis: an immunohistologic studyP J Ford, E Gemmell, A Chan, et al.
Journal of Dental Research|June 4, 2010
High antibody levels to P. gingivalis in cardiovascular diseaseS Bohnstedt, M P Cullinan, P J Ford, et al.
Australian Dental Journal|December 1, 2011
Improved periodontal health and cardiovascular riskS Rose-Hill, P J Ford, S J Leishman, et al.
Protein Science : a Publication of the Protein Society|November 25, 1998
A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinaseT Fox, J T Coll, X Xie, et al.
Pageof 8